Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
Programme II -
Saturday, September 15th, 2012
Breakfast teaching courses
07:30-09:00   Clinical management of Huntington’s disease
Martha Nance (Minneapolis, USA)
07:30-09:00   Differential diagnosis of chorea
Ruth Walker (New York, USA)
07:30-09:00   Behavioral assessment and management of behavioral issues
Karen Anderson (Baltimore, USA)
07:30-09:00   Training on HD assessments including HD-CC
David Craufurd (Manchester, UK), Ralf Reilmann (Münster, Germany), Jennifer Thompson (Manchester, UK) and Oliver Quarrell (Sheffield, UK)

Plenary Session V:
'Understanding and manipulating the pathogenic process in Huntington’s disease'

Chair: David Rubinsztein (Cambridge, UK)
09:15-09:45   Huntingtin
Elena Cattaneo (Milan, Italy)
09:45-10:15   Post-translational modifications of huntingtin
Frédéric Saudou (Paris-Orsay, France)
10:15-10:45   Stem cells for basic research on HD
Lisa Ellerby (Novato, USA), Leslie Thompson (Irvine, USA)
10:45-11:15   Tea/Coffee Break
Plenary Session VI:
'Keynote presentation'

Chair: Neil Aronin (Boston, USA)
11:15-12:00   Updates on lowering huntingtin (htt) levels
Beverley Davidson (Iowa, USA)
12:00-12:30   Open discussion
Poster Viewing
Chairs: Marcy MacDonald (Boston, USA), Marian DiFiglia (Boston, USA), Blair Leavitt (Vancouver, Canada)
12:30-14:00   Poster Viewing & Guided Poster Tours
12:30-14:00   Buffet Style Lunch
Short communications II:
Scientific presentations
Chair: Jim Gusella (Boston, USA)
14:00-14:15   HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplamsic aggregation and rescues synaptic dysfunction in HD mouse models
Gillian Bates (London, UK)
14:15-14:30   Aging pathway and poly-Q neurotoxicity
Ellen Nollen (Groningen, The Netherlands)
14:30-14:45   NeuroNet and its potential for the study of neurodegeneration
Erich Wanker (Berlin, Germany)
14:45-15:00   Phenotyping neural networks in an ovine model of HD
Nicholas Perentos (Cambridge, UK)

Plenary Session VII:
'Therapeutic development programs in Huntington’s disease'

Chair: Cristina Sampaio (Princeton, USA)
15:00-16:30   Overview of CHDI drug development programs
Robert Pacifici (Los Angeles, USA)
  Data blitz
  Htt lowering: Medtronic-Alnylam/Isis/CHDI - Douglas Macdonald
  Sirt1-inhibition: SienaBiotech - Andrea Caricasole
  PDE-10-inhibition: Pfizer - Christopher J. Schmidt
  PDE-4-inhibition: GSK - Frank Gray
  Pridopidine: NeuroSearch - G. Bernhard Landwehrmeyer
  Bupropion: ACTION-HD - Josef Priller
  Further topics
  Round table discussion
Moderation: Robert Pacifici and Cristina Sampaio
16:30-17:00   Tea/Coffee Break
Plenary Session VIII:
'EHDN Business Meeting'

Chair: Stephen Dunnett (Cardiff, UK)
17:00-17:30   EHDN Update
EC elections, SBAC elections
Structure of EHDN
Bernhard Landwehrmeyer (Ulm, Germany)
17:30-17:45   HD guidelines
Daniela Rae (Aberdeen, UK)
17:45-18:00   Presentation of the HDYO website
Matt Ellison (Coventry, UK)
Roundup II
18:00-18:30   Lessons of the day
Edward Wild (London, UK) and Jeff Carroll (Bellingham, USA)

Poster viewing
18:30-22:30   Poster viewing with Bar and Food Buffet